Skip to the main content

Review article

https://doi.org/10.24869/psyd.2026.249

Methylphenidate in the treatment of psychiatric disorders in adults: therapeutic potential and risk of misuse - a narrative review

Julia Nowosielska ; Masovian Specialist Hospital, Poland
Katarzyna Jaczewska ; Lazarski University, The Faculty of Medicine, Warsaw, Poland
Simone Szymczyk ; Masovian Specialist Hospital, Poland
Kacper Król ; Masovian Specialist Hospital, Poland
Anna Marcinkowska ; Masovian Specialist Hospital, Poland
Aleksandra Płusa ; Masovian Specialist Hospital, Poland *
Julia Nowakowska ; Infant Jesus Clinical Hospital, Warsaw, Poland
Borys Nowosielski ; Lazarski University, The Faculty of Medicine, Warsaw, Poland
Kinga Kozioł-Wójcik ; Military Institute of Medicine, Poland
Julia Nosko ; Military Institute of Medicine, Poland

* Corresponding author.


Full text: english pdf 494 Kb

page 249-257

downloads: 0

cite


Abstract

Background: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental condition persisting into adulthood
in up to 60% of affected individuals. Adult ADHD is associated with significant functional impairment, psychiatric comorbidities,
emotional dysregulation, and reduced quality of life. Psychostimulants, particularly methylphenidate, remain first-line pharmacological
therapy, with decades of data supporting their safety and efficacy. Given the evolving understanding of ADHD across the lifespan,
this review synthesizes current evidence on the pharmacological properties, therapeutic potential, and clinical monitoring strategies
for methylphenidate and related stimulants in adults.
Methods: A narrative, concept-driven synthesis was conducted, integrating contemporary clinical knowledge, pharmacological
principles, guideline-level recommendations and outcome-focused treatment principles to adult ADHD.
Results: Methylphenidate inhibits dopamine and norepinephrine transporters, increasing catecholamine availability in frontostriatal
circuits responsible for attention and executive control. Its pharmacokinetic profile differs between immediate-release and
extended-release formulations, allowing individualized treatment. In adults, methylphenidate is indicated for ADHD and occasionally
used off-label in treatment of resistant depression or excessive daytime sleepiness. Treatment usually starts with low doses (10-20 mg/
day), which are titrated according to response and tolerability. Contraindications include uncontrolled hypertension, tachyarrhythmias,
glaucoma, active psychosis and severe anxiety. Benefits include reduced inattentiveness, improved executive functioning and
better occupational and psychosocial outcomes. Careful monitoring - covering cardiovascular parameters, adverse effects, potential
misuse- supports safe long-term use. Across studies, psychostimulants demonstrate high efficacy and good tolerability, contributing to
meaningful improvements in quality of life.
Conclusions: Methylphenidate remains a cornerstone of adult ADHD management, offering predictable pharmacological effects
and flexible dosing when paired with structured clinical monitoring.

Keywords

Methylphenidate; Mental Disorders; Adult; Substance-Related Disorders; Drug Misuse

Hrčak ID:

353620

URI

https://hrcak.srce.hr/353620

Publication date:

17.11.2026.

Visits: 0 *